Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-24-025671
Filing Date
2024-10-28
Accepted
2024-10-28 16:11:50
Documents
2
Period of Report
2024-10-18

Document Format Files

Seq Description Document Type Size
1 form3-10282024_081047.html 3  
1 form3-10282024_081047.xml 3 9360
2 ex24-10282024_081051.htm EX-24 7174
  Complete submission text file 0001415889-24-025671.txt   18054
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Issuer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O SANGAMO THERAPEUTICS, INC. 501 CANAL BLVD. RICHMOND CA 94804
Business Address
Davis Gregory D (Reporting) CIK: 0002041855 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-30171 | Film No.: 241401004